Article

Daily Medication Pearl: Sacituzumab govitecan-hziy (Trodelvy) for Breast Cancer

Sacituzumab govitecan-hziy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.

Medication Pearl of the Day: Sacituzumab govitecan-hziy (Trodelvy)

Indication: Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.

Insight:

  • Dosing: The recommended dose is 10 mg/kg once weekly on days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity.
  • Dosage form: For injection 180 mg lyophilized powder in single-dose vials for reconstitution.
  • Adverse events (AEs): The most common AEs (incidence >25%) are neutropenia, nausea, diarrhea, fatigue, alopecia, anemia, vomiting, constipation, decreased appetite, rash, and abdominal pain.
  • Mechanism of action: Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate. The humanized antibody recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker.
  • Manufacturer: Gilead

Sources:

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Monoclonal antibodies are used to treat lung cancer. They are created in a lab and designed to target specific proteins on cancer cells, stopping them from growing and dividing.
Gene therapy in lung cancer (LC) - isometric view 3d illustration
© 2025 MJH Life Sciences

All rights reserved.